Liquidia Corporation (NASDAQ:LQDA) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET

Company Participants

Jason Adair – Chief Business Officer
Roger Jeffs – Chief Executive Officer
Michael Kaseta – Chief Operating Officer and CFO
Rajeev Saggar – Chief Medical Officer
Rusty Schundler – General Counsel

Conference Call Participants

Julian Harrison – BTIG
Serge Belanger – Needham
Kambiz Yazdi – Jefferies
Matt Kaplan – Ladenburg Thalmann
Jason Gerberry – Bank of America

Operator

Good morning, and welcome, everyone, to the Liquidia Corporation Second Quarter 2024 Financial Results and Corporate Update Conference Call. My name is Lisa, and I will be your conference operator today. Currently all participants are in a listen-only mode. Following the presentation, we will conduct the question-and-answer session. [Operator Instructions] I would now like to remind everyone this conference call is being recorded.

I will now turn – hand the call over to Jason Adair, Chief Business Officer. Please go ahead.

Jason Adair

Thank you, Lisa. It's my pleasure to welcome everyone to Liquidia Corporation's second quarter 2024 financial results and corporate update call. Joining the call today are Chief Executive Officer, Dr. Roger Jeffs; Chief Operating Officer and CFO, Michael Kaseta; Chief Medical Officer, Dr. Rajeev Saggar; Chief Commercial Officer, Scott Moomaw; and General Counsel, Rusty Schundler.

Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results or performance to be materially different from any future results or performance expressed or implied on this call. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website.

I would now like to turn the call over to Roger for our prepared remarks, after which he will open the call for your questions. Roger?

Roger Jeffs

Thank you, Jason. Good morning, everyone. Thank you for joining us today. While we and patients still anxiously await FDA action on the YUTREPIA NDA seeking approval for both pulmonary arterial hypertension, PAH, and pulmonary hypertension associated with interstitial lung disease, or PH-ILD, we remain hopeful that we are close to achieving this. As a reminder, the FDA has hit no legal impediments since April 1st to take action on the amendment as submitted seeking approval for both PAH and PH-ILD.